Revelation Biosciences (REVB) Q1 2025 earnings summary

Executive summary

• Clinical-stage life science company focused on inflammation modulation with proprietary Gemini formulation, targeting acute kidney injury, chronic kidney disease, post-surgical infection, and severe burns.

• Announced new indication for Gemini in severe burn patients and released data showing Gemini priming attenuates inflammation in immune cells.

• Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD patients; topline data expected in summer 2025.

• No revenue generated to date; operations funded by $56.8 million in equity and warrant financings since inception.

• Net loss of $2.1 million for Q1 2025, with an accumulated deficit of $42.6 million as of March 31, 2025.

Financial highlights

• Q1 2025 net loss: $2.1 million, improved from $2.7 million in Q1 2024.

• Operating expenses rose to $2.1 million, up from $1.9 million year-over-year, driven by higher R&D and G&A costs.

• Cash and cash equivalents at March 31, 2025: $3.7 million, down from $6.5 million at year-end 2024.

• Stockholders' equity decreased to $2.9 million from $4.7 million at December 31, 2024.

• Net cash used in operating activities: $2.8 million for Q1 2025, similar to Q1 2024.

Outlook and guidance

• Expects continued operating losses and negative cash flows for the foreseeable future.

• Current cash and cash equivalents expected to fund operations through June 2025; additional capital required thereafter.

• Plans to seek further funding through equity or debt; inability to secure funding may delay or halt development programs.

• Anticipates topline data from the PRIME Phase 1b clinical study in summer 2025.